Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments

NCT02574455 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02574455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02574455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
November 7, 2017
Completion date
December 8, 2020
Enrollment
529 (actual)
Sites
230

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer